Early clinical signals emerged from solid-tumor strategy testing. An oral Wnt-blocking pill combined with lenvatinib showed durable tumor shrinkage in women with advanced endometrial cancer after immunotherapy failure, with results published in EClinicalMedicine from the dose-expansion phase of a global program. In pediatric oncology, clinicians reported a first-ever electrochemotherapy approach in a 7-year-old with high-risk neuroblastoma, described in CVIR Oncology—an early case-based data point that could inform how local therapies are escalated for difficult pediatric tumors. These announcements reinforce how the industry continues to explore combination and local-control strategies in settings where standard lines have limited durability. For clinicians and sponsors, the near-term value is in protocol direction: patient selection and sequence of therapies after immunotherapy or in high-risk pediatric disease remain central decision factors that these reports help shape.